Business
EV Biologics Briefs Shareholders on Market Cap Peer Comparison
EV Biologics Briefs Shareholders on Market Cap Peer Comparison.
About this update from Yulong Eco-materials Limited
[{"type":"text","content":"NASHVILLE, TN / ACCESSWIRE / August 12, 2021 / EV Biologics Corp, OTC Pink:YECO, today briefed shareholders on its current value compared to other public biotechnology companies in its peer group.Please view the chart at: https://www.evbiologics.com/marketcap/.CEO Daniel Mckinney commented: 'Our market cap is less than half that of our closest listed peer. Our goal is to continue to build value and become the largest listed company by market cap in our space within the next 24 months. This target represents a 20X increase from our current market cap.'The Company filed its June 30, 2021 quarterly report today showing $600,000 in cash, posted revenues in Q2, and that it is fully funded with its $5 million line of credit to develop its EVP producer cell lines and scalable biomanufacturing process.EV Biologics is building a world-class team of biotechnology experts specializing in cell and EV biology, biomanufacturing, biochemical engineering, bioinformatics and systems biology.Please visit our website: www.evbiologics.comEV was previously a Nasdaq listed company and intends to apply to up-list to OTCQX before the end of 2021.About the CompanyEV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, intent on developing and enhancing the intrinsic therapeutic activity of mesenchymal stromal cell (MSC) secreted factors, as well as targeted delivery of bioactive molecules using engineered exosomes. The company is working to optimize cell lines for production of native bioactive nanoparticles and to establish an exosome engineering platform to enhance specific therapeutic activity. Initially, these novel regenerative products will be produced for preclinical research on a number of clinical indications. Using proprietary and patentable technologies, the Company is creating exclusive IP and IT inherent in these bioengineered products. Further product development will be focused on investigation of novel stem cell-derived biopharmaceuticals designed for specific clinical conditions.Forward-Looking StatementsThis news release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company's financial position and business strategy. The words or phrases 'plans,' 'wou...